Liminatus Pharma Completes $4 Million Public Equity Offering

Liminatus Pharma ( (LIMN) ) has issued an update.

On February 17, 2026, Liminatus Pharma, Inc. priced a best-efforts public offering of common stock, pre-funded warrants and common stock purchase warrants at a combined price of $0.29 per share and warrant, raising gross proceeds of about $4.0 million. The transaction closed on February 18, 2026, generated approximately $3.46 million in net proceeds after fees, and included lock-up agreements restricting additional equity issuance and insider sales for 180 days, shaping the company’s near-term capital-raising flexibility.

As part of the deal, Maxim Group LLC acted as sole placement agent, receiving an 8.0% cash fee, expense reimbursement and placement agent warrants equal to 5.0% of the shares sold, exercisable at a premium to the offering price for five years. Liminatus plans to deploy the new capital toward clinical trials, research and development, sales and marketing, and general working capital needs, supporting the advancement of its pipeline while modestly diluting existing shareholders and potentially providing further funding if investor warrants are exercised.

More about Liminatus Pharma

Liminatus Pharma, Inc. is a pre-clinical stage immuno-oncology company listed on Nasdaq under the ticker LIMN. It focuses on developing next-generation CD47-blockade therapies, including its proprietary antibody IBA101, aimed at overcoming the limitations of first-generation immune therapies in treating solid tumors.

Average Trading Volume: 7,399,938

Technical Sentiment Signal: Sell

Current Market Cap: $11.68M

Find detailed analytics on LIMN stock on TipRanks’ Stock Analysis page.